Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Abstract: An ensemble time series prediction system that makes predictions based on observed data. The disclosed ensemble time series prediction system may leverage different types of datasets and information from different resources for making predictions. The disclosed ensemble time series prediction system may extract time dependent features from autoregressive time dependent data, embedding features from sparse datasets, continuous features from continuous dataset, and time lagged features from data that include time-lag information. The disclosed ensemble time series prediction system may then consolidate the features extracted from the different types of datasets and generate a set of consolidated input features for training a neural network, which may include a recurrent neural unit that finds sequential pattern for the sequence of input features and a regression unit that performs regression and predictions.

Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.

Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: Automated response generation systems and methods are disclosed. The systems can include a deep learning model specially configured to apply embedding techniques to redesign natural language querying systems for use over knowledge graphs. The disclosed systems and methods employ knowledge graph embedding to reduce knowledge graph sparsity by performing missing link prediction. The systems and methods described generate query graphs with increased flexibility and the ability to handle multi-hope constrained-based queries.

Abstract: A system according determines a machine learning based model for forecasting time series data for a given use case. The system determines a model metric for a specific use case of time series data. The system accesses a pool of machine learning based models including a plurality of machine learning based models machine learning based models based on different machine learning techniques. For each of the plurality of machine learning based models the system performs forecasting using the machine learning based model and determines the value of the model metric for the machine learning based model. The system selects a machine learning based model based on comparison of values of the model metric for machine learning based models. The system uses the selected machine learning based model for forecasting values for the time series data for the application.

Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: An Artificial Intelligence (AI)-based data matching and alignment system identifies similar data sources for a target data source from a data corpus and generates a knowledge graph that enables downstream applications seamless access to data in the data corpus. The system extracts column features at different levels for the target data source and a plurality of data sources from the data corpus. Feature matrices are built from the features of the target data source and the plurality of data sources. Candidate data sources similar to the target data source are filtered from the plurality of data sources using the feature matrices. The tree-based similarity is estimated and K Nearest Neighbor (KNN) graphs are built to identify columns from the candidate data sources that are similar to columns of the target data source to build the knowledge graph.

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Abstract: Spin columns that include a poly(acid) membrane separation matrix are provided. Also provided are kits that include the subject devices, as well as methods of using the devices, e.g., in sample preparation (such as protein purification) protocols.

Abstract: Dry, e.g., lyophilized, polymeric transfection agent compositions are provided. The dry compositions include a polymeric transfection agent and a buffer. In some instances, the compositions further include one or more nucleic acids. Also provided are methods of making and using the compositions, as well as kits including the compositions.

Abstract: Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.

Abstract: Spin columns that include a poly(acid) membrane separation matrix are provided. Also provided are kits that include the subject devices, as well as methods of using the devices, e.g., in sample preparation (such as protein purification) protocols.

Abstract: Spin columns that include a poly(acid) membrane separation matrix are provided. Also provided are kits that include the subject devices, as well as methods of using the devices, e.g., in sample preparation (such as protein purification) protocols.